Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Intra-Cellular Therapies: Clinical Trials & FDA Approval Profile

Intra-Cellular Therapies (Global / Institutional) sponsors 21 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 12 active protocols (11 recruiting now), 9 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)480 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Intra-Cellular Therapies
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)21
Active Pipeline (Recruiting Now)12 (11)
Completed vs Stopped Early9 / 0 (0.0%)
Median Closed Actual Enrollment480 participants
Physical Hospital Site Disclosure56.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Intra-Cellular Therapies
Hospital Research SiteLocationShared Protocols
Northwest Clinical Research CenterBellevue, WA7
Advanced Research Center, Inc.Anaheim, CA5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Intra-Cellular Therapies
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06229210Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderPhase IIIRECRUITING
NCT06372964Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsPhase IIIRECRUITING
NCT06690398Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsPhase IIIRECRUITING
NCT05850689Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPhase IIIRECRUITING
NCT06706674Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric PatientsPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Intra-Cellular Therapies Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI